Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Black Diamond Therapeutics, Inc. (BDTX) had Normalized Pre-Tax Income of $-82.44M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-82.44M |
|
-- |
|
-- |
|
$86.46M |
|
$-86.46M |
|
$4.02M |
|
$-82.44M |
|
|
Normalized Pre-Tax Income |
$-82.44M |
$-82.44M |
|
$-82.44M |
|
$-82.44M |
|
$-82.44M |
|
$-86.46M |
|
$-86.02M |
|
43.95M |
|
43.95M |
|
$-1.88 |
|
$-1.88 |
|
| Balance Sheet Financials | |
$134.03M |
|
$1.73M |
|
$24.53M |
|
$158.57M |
|
$19.65M |
|
-- |
|
$22.18M |
|
$41.83M |
|
$116.74M |
|
$116.74M |
|
$116.74M |
|
51.65M |
|
| Cash Flow Statement Financials | |
$-66.72M |
|
$16.35M |
|
$71.93M |
|
$35.48M |
|
$57.04M |
|
$21.56M |
|
$9.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-66.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-70.62% |
|
-70.62% |
|
-51.99% |
|
-70.62% |
|
$2.26 |
|
$-1.52 |
|
$-1.52 |
|